Transcranial Photobiomodulation with Near-Infrared Light for Generalized Anxiety Disorder: A Pilot Study
Author(s) -
Marco Maiello,
Olivia M Losiewicz,
Éric Bui,
Vincenza Spera,
Michael R. Hamblin,
Luana Marques,
Paolo Cassano
Publication year - 2019
Publication title -
photobiomodulation photomedicine and laser surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.319
H-Index - 9
ISSN - 2578-5478
DOI - 10.1089/photob.2019.4677
Subject(s) - pittsburgh sleep quality index , anxiety , clinical global impression , mood , transcranial magnetic stimulation , medicine , anxiolytic , generalized anxiety disorder , psychology , sleep quality , psychiatry , cognition , alternative medicine , pathology , stimulation , placebo
Objective: Our aim was to test the anxiolytic effect of transcranial photobiomodulation (t-PBM) with near-infrared light (NIR) in subjects suffering from generalized anxiety disorder (GAD). Background: t-PBM with NIR is an experimental, noninvasive treatment for mood and anxiety disorders. Preliminary evidence indicates a potential anxiolytic effect of transcranial NIR. Methods: Fifteen subjects suffering from GAD were recruited in an open-label 8-week study. Each participant self-administered t-PBM daily, for 20 min (continuous wave; 830 nm peak wavelength; average irradiance 30 mW/cm 2 ; average fluence 36 J/cm 2 ; total energy delivered per session 2.9 kJ: total output power 2.4 W) broadly on the forehead (total area 80 cm 2 ) with an LED-cluster headband (Cerebral Sciences). Outcome measures were the reduction in total scores of the Hamilton Anxiety Scale (SIGH-A), the Clinical Global Impressions-Severity (CGI-S) subscale and the Pittsburgh Sleep Quality Index (PSQI) subscales from baseline to last observation carried forward. Results: Of the 15 recruited subjects (mean age 30 ± 14 years; 67% women), 12 (80%) completed the open trial. Results show a significant reduction in the total scores of SIGH-A (from 17.27 ± 4.89 to 8.47 ± 4.87; p < 0.001; Cohen's d effect size = 1.47), in the CGI-S subscale (from 4.53 ± 0.52 to 2.87 ± 0.83; p < 0.001; Cohen's d effect size = 2.04), as well as significant improvements in sleep at the PSQI. t-PBM was well tolerated with no serious adverse events. Conclusions: Based on our pilot study, t-PBM with NIR is a promising alternative treatment for GAD. Larger, randomized, double-blind, sham-controlled studies are needed.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom